Skip to main content
logo
Anebulo Pharmaceuticals, Inc. (ANEB)
OTCMKTS · Delayed Price · Currency is USD
0.3300
0.00 (0.00%)
Jul 28, 2026, 9:32 AM EST

Anebulo Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jul - Jun.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Cash & Equivalents
9.0411.633.0911.2514.5519.99
Cash & Short-Term Investments
9.0411.633.0911.2514.5519.99
Cash Growth
-39.72%275.80%-72.49%-22.69%-27.21%560.69%
Other Receivables
0.060.07----
Total Trade Receivables
0.060.07----
Other Current Assets
0.180.260.410.421.031.67
Total Current Assets
9.2711.963.5111.6715.5821.65
Other Long-Term Assets
0.150.180.57---
Total Assets
9.4212.154.0711.6715.5821.65

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Accounts Payable
0.550.220.160.530.380.11
Accrued Expenses
0.930.260.10.530.130.13
Total Current Liabilities
1.490.490.261.070.510.24
Total Liabilities
1.490.490.261.070.510.24

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Common Stock
--0.030.030.020.02
Additional Paid-in Capital
--69.1967.7860.5160.03
Retained Earnings
-78.05-73.89-65.4-57.2-45.47-38.64
Total Common Shareholders' Equity
7.9411.663.8110.615.0721.41
Shareholders' Equity
7.9411.663.8110.615.0721.41
Total Liabilities & Equity
9.4212.154.0711.6715.5821.65

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Net Cash (Debt)
9.0411.633.0911.2514.5519.99
Net Cash Growth
-39.72%275.80%-72.49%-22.69%-27.21%607.78%
Net Cash Per Share
0.220.340.120.450.621.47
Book Value
7.9411.663.8110.615.0721.41
Book Value Per Share
0.190.340.150.420.651.57
Tangible Book Value
7.9411.663.8110.615.0721.41
Tangible Book Value Per Share
0.190.340.150.420.651.57